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ABSTRACT 
Objective: The objective of the present study was to design and optimize oral fast dissolving film (OFDF) of practically insoluble drug lafutidine in 
order to enhance bioavailability and patient compliance especially for a geriatric and unconscious patient who are suffering from difficulty in 
swallowing.  
Methods: The films were prepared by a solvent casting method using low-grade hydroxyl propyl methyl cellulose (HPMC E5), polyvinyl alcohol 
(PVA), and sodium carboxymethyl cellulose (SCMC) as film forming polymers. Polyethylene glycol 400 (PEG400), propylene glycol (PG) and glycerin 
were used as a plasticizer to enhance the film forming properties of the polymer. Tween 80 (1% solution) and poloxamer407 were used as a 
surfactant, citric acid as a saliva stimulating agent, and croscarmellose as a super disintegrant. Films were then tested for both physical (weight 
variation, thickness, surface pH, drug content) and mechanical (folding endurance, tensile strength, percent elongation, Young's modulus) 
characteristics. In vitro disintegration, time and drug release profile were also determined for each formula.  
Results: Films were found to be satisfactory when evaluated for both physical and mechanical characterizations. The surface pH of all the films was 
found to be within the range of salivary pH 6.8. The USP dissolution apparatus type II (paddle type) was used for in vitro drug release studies. The 
optimized formulation F13 gave 100 % of drug released at 2 min. It also showed satisfactory surface pH (6.2±0.2), drug content (100.1±0.01%), the 
disintegration time of (7.0±0.5) seconds and the time needed for 80% of medication to be released (T80%) was 0.96 min. 
Conclusion: Lafutidine OFDF was formulated using HPMC E5 as film-forming a polymer with PEG400 as a plasticizer. Combination of tween80 (1% 
solution) and poloxamer407 as a surfactant were used in the presence of croscarmellose as a super disintegrant. The chosen OFDF disintegrates 
within seven seconds, releases the drug rapidly and gives an action. 
Keywords: Lafutidine, Oral fast dissolving film, OFDF, Solvent casting method 




Oral administration is one of the most crucial routes of 
administering a drug with high credit to obtain a systemic effect due 
to it̓s simplicity, comfort ability by producing no pain compared 
with the systemic administration. However, disadvantages in case of 
certain oral dosage forms capsules and tablets, such as swallowing 
problems especially for children, infants and elderly leading to in 
compliance and disadherence to the treatment [1]. Approximately 
35% of the population showed dysphagia and troubles with 
swallowing also people with hiccups, gagging, sea/motion sickness, 
and obstruction of the esophagus pathway will be forced to search 
for other alternatives which favor the systemic drug delivery such as 
fast-dissolving medication [2]. 
Oral fast dissolving films (OFDFs) are the most advanced form of an 
oral solid dosage form, which disintegrate or dissolve within a 
minute when placed in the mouth without drinking water or 
chewing. The anatomical composition of the buccal cavity, high 
blood flow as well as the high permeable nature of the buccal 
mucosa make using of such dosage forms have quite privileges such 
as rapid onset, with immediate bioavailability [3]. 
Oral films are formulated using polymers, plasticizer, flavors, colors, and 
sweeteners. Hydrophilic polymers are rapidly disintegrated or dissolved 
in the oral cavity delivering the drug to the systemic circulation that was 
used in the preparation of OFDFs. Plasticizer helps to enhance the 
flexibility and reduces the brittleness of the strip [4]. 
Lafutidine is a new H2-receptor antagonist, after absorption in the 
small intestine, it reaches gastric cell by the systemic circulation, 
then directly and quickly binds to gastric cell H2-receptor resulting 
in promote inhibition of gastric acid secretion. The drug is 
predominantly metabolized in the liver by microsomal enzyme 
CYP3A4 and CYP2D6. Its major metabolites are hydroxylated 
lafutidine and sulfonyl lafutidine [5, 6]. Its maximum plasma 
concentration of 133.9±8.1 (ng/ml) will be reached at time of 
(1.844±0.334) h [7]. It has a biological half-life of 1.92 h [8]. 
Lafutidine has a receptor binding affinity which is 2-80 times higher 
than other representative H2-receptor antagonists (e. g. famotidine, 
ranitidine and cimetidine) [9]. 
Lafutidine exerts gastroprotective effects independent of its 
antisecretory action by increasing intracellular Ca 2+ion concentration in 
endothelial cell that provokes the release of neurotransmitters CGRP 
which stimulate nitric oxide(NO) production in endothelial cell,where 
NO plays a role in the control of gastric mucosal blood flow by 
vasodilatation within the gastric microvasculature [10]. 
Lafutidine has been found to significantly increase plasma somatostatin 
level at (0.3-2) h after administration where somatostatin inhibites 
gastric acid secretion by acting directly on its receptor on a parietal cell 
and indirectly by decreasing gastrin from antral G cell [9]. 
The aim of this study was to formulate and in vitro evaluate an OFDF 
of practically insoluble lafutidine to enhance itʼs solubility, improve 
compliance and bioavailability as well as to produce an immediate 
release action of lafutidine from the film for an efficient management 
of gastric ulcers,duodenal ulcers and gastric mucosal lesions 
combined with acute or chronic gastritis. 
MATERIALS AND METHODS 
Material 
Lafutidine and Poloxamer 407 were purchased from Hangzhou 
Hyper Chemicals Limited, Zhejiang; China. HPMC E5, PVA, and SCMC 
were supplied from Samarra Drug Industry (SDI) as a gift. Glycerin 
and PEG400 were purchased from Fluka Chemical AG, Switzerland. 
PG was purchased from Evans Medical Ltd, Liverpool, England. All 
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other chemicals and solvents were of analytical reagent grade, and 
deionized water also was used in this study. 
Method 
Construction of calibration curve 
Calibration curve for lafutidine in phosphate buffers (pH 6.8) were 
made by preparing serial dilutions of the drug from a stock solution 
(0.48 mg/ml). Samples (9.6, 19.2, 38.4, 48, 57.6 and 76.8 µg/ml) 
were then analyzed spectrophotometrically for lafutidine at its λmax 
(273 nm) [11]. 
Method for preparation of lafutidine OFDF 
Fourteen formulas were prepared (F1-F14) as listed in table 1 by 
using the solvent casting method; every film of about 4 cm2 area 
must contain 10 mg of lafutidine. The size and number of films that 
formulated for every group designed as the following:  
The dose of the drug to be incorporated in each 4 cm2
Area of Petri dish = π r
 film = 10 mg 
of lafutidine. 
The diameter of petri dish is 11 cm, so that the radius = 5.5 cm. 
2, 3.14 × (5.5 cm)2 = 94.985 cm2 
approximately 95 cm2
A number of 4 cm
. 
2 films obtained from the main film =95 cm2 ÷ 4 
cm2 = 23.75 films approximately 24 films each with area 4 cm2
The amount of lafutidine should be incorporated in the area 
considered is calculated as follow:  
. 
24 film × 10 mg =240 mg. 
The OFDFs of lafutidine were prepared by a solvent casting method. 
The considered quantity of film-forming polymer was dissolved in 
20 ml of solvent (distilled water) with constant stirring using a 
magnetic stirrer for two h to form a homogenous polymeric solution. 
To this polymeric solution, a suitable amount of plasticizer was 
added with continuous stirring for another one h. In another beaker, 
the drug was dissolved in 8 ml mixture of (0.1N HCL and 1% 
tween80 solution) to form a clear solution; then the volume was 
completed to 10 ml with distilled water. Saliva stimulating agent, 
sweetener and superdisintegrant were added to the drug solution. 
The two solutions (polymer and drug) were mixed using a magnetic 
stirrer for one h; then it was kept in a sonicator for degassing. The 
bubble-free solution was cast on to a petri dish with a diameter of 11 
cm2
  
 and kept in hot air oven (60̊ C) overnight. The dried film was 
then removed and cut into the desired shape and size (2 cm × 2 cm) 
for the intended application. Cuts or defectiveness were omitted 
from the study [12]. 
Table 1: Composition of lafutidine oral films formulas 
Ingredients present in each film (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
Lafutidine 10 10 10 10 10 10 10 10 10 10 10 10 10 10 
HPMC E5 25   25 25 25 25 25 25 25 25 25 25 25 
PVA  25  25 12.5          
SCMC   25   12.5         
PEG 400 7.5 7.5 7.5 7.5 7.5 7.5 8.5 6 4   7.5 7.5 7.5 
Glycerin          7.5     
PG           7.5    
Tween 80 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6  1.6 1.6 
Poloxamer407            1.6 1.6 1.6 
Croscarmellose 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5  
Citric acid 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Vanilla 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Sodium saccharin 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
Evaluation of lafutidine OFDF  
Physical characterization of the prepared films 
Physical characteristics such as color, thickness, brittleness, peeling 
ability, transparency, surface smoothness, tack property and film-
forming capacity can be carried out by visual inspection for all the 
above characteristics [13]. 
Weight variation 
The uniformity of the film formed was confirmed by weight 
variation test. Ten randomly selected films from each patch (each of 
2 cm × 2 cm) were weighed individually and matched with the mean 
weight for deviation [14]. 
Thickness measurements 
Digimatic and Vernier Caliper was used to measure the film thicknesses. 
Each film was measured at five positions (central and the four corners) 
the mean thickness was calculated. This test was performed on six films 
of each formulation and mean±S. D calculated [15]. 
Drug content uniformity  
Drug content was determined by taking three films from each 
formulation patch randomly and weighed individually. Each film 
was dissolved in 5 ml of methanol, sonication; the volume was 
completed to 10 ml with distilled water then filtered through 
0.45μm filter syring. Using 100 ml volumetric flask, 1 ml of the 
filtrate was diluted with distilled water to the mark and analyzed 
spectrophotometrically at λmax (279 nm). The average drug content 
was calculated [16]. 
Determination of surface pH  
Surface pH determination is important to investigate any side effects 
when using the OFDFs in vivo, due to the irritation of the mucosal 
membrane of an oral cavity by acidic or basic pH. OFDFʼs pH value 
was measured by dissolving one film in 2 ml of distilled water and 
the solutionʼs pH was determined using Schott Gerate pH-meter. 
Different pH value will be expected because of the fact of using a 
different film forming polymers in the formulation of OFDFs along 
with the drug [17]. 
Folding endurance 
The number of time the film is folded without breaking is known as 
the folding endurance value. Folding endurance is measured by 
manual repeated folding of the film at the same place till it broke. A 
film of an area of 4 cm2
Tensile strength 
was subjected to folding endurance by folding 
the film at the same place several times repeatedly until a visible 
crack was observed and the average values were calculated and 
reported. The value of folding endurance of more than 300 
indicating that the formulation is good, tough and flexible [18].  
Define as the maximum value of forces applied on the film to breaks 
down. Tensometer was used to measure the tensile strength by 
holding a film of 5 cm × 2 cm (which must be pure from air bubbles 
or any physical defectiveness and cut as dumbbell-shaped) 
longitudinally in it, then it was drawn at a level of 10 mm/min. 
Mathematically measurement of the tensile strength by dividing the 
applied force at which the film was broken on the cross-section area 
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of it, as shown in the following equation. Mega Pascal (MPa) is a unit 
of tensile strength [19]. 
Tensile Strength = Load to Break/Width × Thickness × 100 
Percentage elongation 
The deformation of the film divided by the original dimension of it 
known as a strain which is referred to the stretches of the sample 
when stress is applied. Elongation related to the stretching of the 
film sample when stress is applied. As the plasticizer concentration 
increases the elongation of the film increases too. Percentage 
elongation (%E) was calculated by measuring the increase in the 
length of the film after tensile strength measurement by using the 
following formula [20]. 
Percentage Elongation (%E) = [Final length-Initial length] X 
100/Initial length 
Young's modulus  
Measuring the stiffness of the film is referred to young's modulus or 
elastic modulus. It is represented as the ratio of applied stress over 
strain in the region of elastic deformation as follows:  
Young’s modulus = Slope X 100/Strip thickness X Cross-head speed 
Hard and brittle film demonstrates high tensile strength and Young's 
modulus with small elongation [21]. 
Percent moisture absorb (PMA)  
The physical stability of the film at high humid conditions was 
determined by this test. In the present study, the moisture absorption 
capacity of the lafutidine OFDFs was determined by keeping the pre-
weighed films in the desiccator containing a saturated solution of 
potassium chloride, which maintains 79.5% relative humidity at room 
temperature for 72 h. Average percentage moisture absorption of three 
films can be calculated by the following equation [22]:  
 
In vitro disintegration time (DT) 
The time at which the OFDF starts to break down or disintegrate is 
known as the DT. It was measured by a petri dish method. The test was 
done by taking three films from each formula then in a petri dish 2 ml of 
distilled water was adding for each film, it was shaken continuously, then 
measure the time at which the OFDF starts to break down or 
disintegrate. It was done in triplicate for all the formulations [23].  
In vitro dissolution study 
The dissolution study was carried out using USP type II (paddle 
apparatus) with 200 ml of phosphate buffer pH 6.8 as a dissolution 
medium maintained at 37±0.5˚C. The medium was stirred at 50 rpm 
for a period of 20 min. Samples were withdrawn by using a syringe 
fitted with a microfilter (0.45 μm) at regular intervals (1, 2, 3, 4, 5, 
10, 15 and 20 min) replaced with fresh medium in order to maintain 
sink conditions. Samples were analyzed spectrophotometrically at 
273 nm for the drug content. Cumulative percent of lafutidine 
released was calculated and plotted against time [24]. 
Statistical analysis  
The results of the experiments are given as a mean of triplicate 
samples±standard deviation and were analyzed according to the one 
way analysis of variance (ANOVA) at the level of (P<0.05) to determine if 
the changes in the applied factors are statistically significant at level of (P 
≤ 0.05) and non-significant at level of (p>0.05). 
RESULTS AND DISCUSSION  
Visual inspection 
All the prepared OFDFs which contain HPMC E5, PVA, and SCMC showed 
homogenous and smooth surface properties, where as HPMC and PVA 
films were transparent, colorless, thin and soft while those prepared 
from SCMC were thin, soft, colorless and semi-transparent. 
Weight variation 
The average weights for all the prepared formulations were uniform 
and fit to the referred values as shown in table 2, so the strategy 
utilized for the preparation of films is reproducible and give films of 
uniform weight. Digital balance was used to determine the weight of 
the films, all show consistency. 
Thickness 
The average thickness values of films for all formulas were shown in 
table 2. The thickness was found to vary between (0.08±0.02) to 
(0.16±0.01) mm. A very low standard deviation value is indicating 
that the method used for the formulation is reproducible and give 
films of uniform thickness, hence dosage accuracy in each film can 
be ensured. 
Drug content 
The formulated lafutidine films showed an acceptable quantity of 
medicament ranged from (96.8±0.4 %) to (102.2±0.2 %) as shown 
in table 2. The accepted range of content uniformity labeled in BP is 
ranged from 85 % to 115 %. The results is obeying this range, which 
indicating that the solvent casting method used in preparing of 
lafutidine OFDFs is very efficient. So the drug was spread uniformly 
throughout the 4 cm² constant area of the films. 
Surface pH measurement 
All the prepared films showed an acceptable surface pH value 
(6.1±0.2) to (6.5±0.1) as viewed in table 2 when compared to the pH 
of oral mucosa indicating that it does not cause an irritation to it. 
Percent moisture absorb (PMA) 
Moisture uptake holds a critical investigation on drug stability. All 
the reported values of moisture uptake are listed in the table 2. It 
was detected that all the polymers were hydrophilic in nature and 
the moisture absorb values ranged from (1.0±0.6 %) to (9.4±0.1%). 
  
Table 2: Physical evaluation parameters of lafutidine OFDFs formulas 
Formula code Weight 
variation (mg) ***  








F1 52.64±0.01 0.08±0.02 100.1±0.1 6.3±0.5 8±0.5 3.8±0.55 
F2 52.93±0.1 0.11±0.01 99.6±0.2 6.2±0.3 10±0.2 4.0±0.6 
F3 52.11±0.2 0.1±0.02 98.2±0.5 6.2±0.2 16±0.4 6.6±0.32 
F4 71.86±0.4 0.16±0.01 100.5±0.2 6.2±0.3 300±0.6 9.4±0.1 
F5 61.4.±0.6 0.13±0.02 100±0.1 6.1±0.2 108±0.4 5.8±0.25 
F6 61.9±0.05 0.12±0.04 101±0.2 6.2±0.3 78±0.1 7.2±0.2 
F7 53.63±0.2 0.11±0.01 99.9±0.1 6.3±0.5 7±0.5 4.4±0.3 
F8 51.8±0.6 0.09±0.02 98.1±0.2 6.2±0.4 10±0.5 4.2±0.32 
F9 52.2±0.02 0.08±0.05 102.2±0.2 6.0±0.5 12±0.4 5.1±0.6 
F10 52.28±0.1 0.09±0.02 96±0.4 6.5±0.1 15±0.5 6.0±0.45 
F11 52.0±0.5 0.09±0.03 101±0.1 6.2±0.4 10±0.2 5.09±0.3 
F12 52.5±0.06 0.09±0.03 96.8±0.4 6.3±0.1 11±0.2 4.8±0.6 
F13 55.32±0.01 0.09±0.02 100±0.01 6.2±0.2 7±0.5 5.0±0.25 
F14 51.32±0.01 0.08±0.01 98.6±0.2 6.3±0.1 9.8±0.2 4.4±0.3 
All values were calculated as mean±SD,* n=3, ** n=6, *** n=10  
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Table 3: Mechanical properties of lafutidine OFDFs formulas 
Formula code Folding endurance Tensile strength  Percent of elongation  Young's modulus. 
F1 450±5.5 6.5±0.2 21.1±0.2 105±0.3 
F2 500±4.5 16±0.1 28.3±0.6 110.6±0.4 
F3 800±6.4 19±0.12 30.1±0.5 116±0.8 
F4 600±10 22±0.8 28±0.8 120±2.5 
F5 800±8.0 18±0.5 26±0.5 116±3.1 
F6 1200±12 20±0.3 32±0.6 118±1.5 
F7 600±3.4 4.6±0.4 25.5±0.3 88±2.1 
F8 400±2.6 6.1±0.3 19.8±0.8 102±0.2 
F9 150±1.5 5.2±0.4 14.2±0.6 111.5±0.8 
F10 380±2.5 7.6±0.5 18.5±0.3 112.5±0.5 
F11 400±3.5 8.2±0.7 17.4±0.2 115.4±0.3 
F12 370±1.5 4.4±0.2 18.6±0.2 88±2.1 
F13 359±2.0 5.4±0.1 18.9±0.6 86.8±0.5 
F14 480±0.6 4.4±0.2 17.5±0.6 89±0.6 
All values were calculated as mean±SD, n=3 
 
Effect of different types of polymers 
As shown in table 1 formulas (F1, F2 and F3) were utilized to study 
the effect of polymer type (HPMC E5, PVA, and SCMC) with 
concentration (50% w/w of the total dry weight) on the physical 
and mechanical properties of the prepared lafutidine OFDFs as well 
as their effect on the drug release profile. 
According to the results obtained, potential differences could be 
investigated between the three polymers without changing their 
ratio in the prepared film, also variation in the DT and mechanical 
characteristics could be identified in order to select the polymer that 
has the best film forming properties. The mechanical properties of 
OFDFs are very essential since it related to their stability during 
storage, shipping, and packaging. 
A high % E value shows that the film is flexible and tough. Tensile 
strength has been utilized as a marker of the general mechanical 
prevalence of the film. Folding endurance test results indicated that 
the films would maintain the integrity with buccal mucosa when 
applied and has good plasticity. This makes the system acceptable 
for movement of the mouth, indicating good strength and elasticity. 
The selected OFDFs must have reasonable tensile strength, high % E, 
low youngʼs modulus, short DT and a high percent of drug release. 
The results in the table 2 showed that the DT of formulas F1, F2 and 
F3 were 8, 10 and 16 s respectively, this indicates that F1 gave the 
shortest DT in the mouth compared to the other formulas [25]. 
Except for PVA the retardation in disintegration is due to the 
swelling property of this polymer which makes a gel-like layer on 
the surface of the film upon contact with aqueous media leads to 
preventing penetration of water to the film, this swelling property 
increased with increasing the polymer concentration [26]. 
So different film-forming polymers gave different DT value as shown 
in the fig. 1: 
 
 
Fig. 1: In vitro disintegration time of different film-forming polymers, (mean±SD, n=3) 
 
As expressed in table 3 in which the mechanical properties of OFDFs 
are listed, the film prepared with HPMC E5 (F1) as film-forming 
polymer gave satisfactory % E (21.1±0.2), excellent folding endurance 
value (450±5.5), with low value of youngʼs modulus (105±0.3) and the 
tensile strength, is about (6.5±0.2), these outcomes were in 
concurrence with those that reported by Tamer et al. [27].  
Formula F2 prepared with PVA as film-forming polymer exhibited a 
high %E (28.3±0.6), and good folding endurance (500±4.5). High 
values of youngʼ The difference in dissolution may be attributed to the difference in 
composition of film-forming materials [25]. 
s module and tensile strength were (110.6±0.4) and 
(16±0.1) respectively while the films prepared with SCMC as film 
forming polymer exerts higher values of folding endurance 
(800±6.4), %E (30.1±0.5), Young's modulus (116±0.8) and tensile 
strength (19±0.12) as shown in table 3. These findings agreed with 
the results reported by Chinnala et al. [28]. 
Fig. 2 showed the dissolution profile of formulas (F1, F2 andF3), it 
was clear that the cumulative percentage of lafutidine released from 
the investigated polymers would be as follow: F1>F2>F3.  
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F1( HPMC E5  50%)
F2 ( PVA 50%) 
F3 ( SCMC 50%)
 
Fig. 2: Effect of polymer type on the dissolution profile of lafutidine in phosphate buffer (pH 6.8) at 37 °C,(mean±SD, n=3) 
 
The values of T80% (time needed for 80% of medication to be 
released) for F1, F2 and F3 were 1.68, 1.9 and 1.87, min respectively, 
as well as the values of % D2 min (percentage medication released 
in 2 min) were 95%, 84% and 85.4% respectively as listed in table 4. 
  
Table 4: In vitro dissolution parameters from the prepared OFDFs (F1, F2 and F3) 
Formula T80% (min) D2 min (%) 
F1 1.68±0.1 95±0.2 
F2 1.9±0.15 84±0.25 
F3 1.87±0.2 85.4±0.4 
 All values were calculated as mean±SD, n=3, from all these results we found that HPMC E5 (F1) had the best physical, mechanical properties and 
drug release profile than the other film forming polymers. 
 
Effect of selected polymer (HPMC E5) combination 
According to the physical, mechanical properties, and the drug 
release profile, HPMC E5 (F1) was selected as an optimized suitable 
polymer for preparing of lafutidine OFDF. 
Formulas F4, F5 (HPMC E5 with PVA in a ratio of 1:1 and 1:0.5 
respectively) and F6 (HPMC E5 with SCMC in 1: 0.5 ratio) were 
further evaluated to get an optimum suitable polymer combination 
by studying their physical, mechanical and the dissolution profile 
parameters.  
Table 2 revealed that there is a significantly (p ≤ 0.05) increased in 
the in vitro DT of the formulated OFDFs with increasing the ratio of 
polymer combination with HPMC E5 from F4>F5>F6.  
Fig. 3 showed that films containing a high concentration of polymer 
(HPMC E5 with PVA) resulted in a thicker gel upon contact with the 
medium, leading to longer DT except for SCMC with HPMC E5 which 
is more water soluble than PVA in the same ratio [29]. This was 
agreed with the result obtained from metoprolol tartrate strips and 
lamotrigine fast dissolving films [30, 31]. 
  
 
Fig. 3: In vitro disintegration time of different polymer combination with the selected film-forming a polymer (HPMC E5), (mean±SD, n=3) 
Jabir et al. 
Int J App Pharm, Vol 10, Issue 5, 2018, 249-260 
 
254 
The outcomes listed in table 3, indicate that film with high value of 
tensile strength result from increasing the polymer concentration is 
due to the fact that densely packed chains of HPMC produced from 
polymer combination make the film need more force to breaks [32]. 
These findings agreed with the results obtained by Kazan et al. [33]. 
Also high % E and higher folding endurance of the films were 
detected upon a combination of polymers as shown in table 3,which 
is due to increase in the elasticity nature of the polymer [28]. Similar 
observations were found by Trivedi J et al. [34]. 
Table 5 shows that formula (F1) has the highest D2 min (95%) and 
the lowest T80% (1.68 min) indicating that F1 which formulated 
only with HPMC E5 as a film-forming polymer gave fastest 
dissolution rate compared with the F4, F5 and F6 which formulated 
using different ratio of polymer combination with HPMC E5. 
 
Table 5: In vitro dissolution parameters from the prepared OFDFs (F1, F4, F5, and F6) 
Formula code T80% (min) D2 min (%) 
F1 1.68±0.5 95±0.2 
F4 6.9±0.5 70.6±0.2 
F5 2.9±0.25 78±0.55 
F6 2.94±0.3 76.3±1.25 
All values were calculated as mean±SD, n=3 
 
From the dissolution parameters that shown in table 5 for the 
formulas (F1, F4, F5 and F6) prepared with a different combination 
ratio of each polymers (PVA, SCMC) with HPMC E5,it was clear that 
the dissolution rate of lafutidine reduces significantly (p<0.05) as 
the ratio of polymer combination with HPMC E5 increases from 1: 
zero in formula (F1) to 1:1 in formula (F4) as shown in fig. 4, this 
result may be due to the fact that higher concentration of polymers, 
produce a high consistency gel layer created by close interaction 
between the particles resulting in a diminished movement of 
medication particles in swollen lattices, which prompt a decline in 
dissolution rate [32]. 
The percentage of lafutidine released from the investigated polymer 
combination would be higher for formula as follow: F1>F6>F5>F4. 
Therefore, F1 which contain only HPMC E5 (50 % w/w) with 0% of 
other polymers was considered as the best polymer chosen for the 
design of the subsequent formulas through the study. 
 
 
Fig. 4: Cumulative percentage of lafutidine released from different combination of polymer with HPMC E5 in phosphate buffer (pH 6.8) at 
37 °C, (mean±SD, n=3) 
 
Effect of the plasticizer type  
Formulas (F1, F10, and F11) were employed to study the effect of 
different plasticizer types at a certain concentration 30% w/w (PEG 
400, glycerin, and PG) on the physical and mechanical properties of 
the prepared lafutidine OFDFs as well as their effect on the drug 
release profile. 
The results indicate that no significant changes (p>0.05) were 
shown on the in vitro DT of the OFDF upon changing of plasticizer 
type as shown in fig. 5, this may be due to the fact that penetration of 
fluid into the film was facilitated by the three types of plasticizer 
since the densely packed chains of HPMC were altered by the 
plasticizer through forming a polymer structure possess more pores 
and less densely that breaks at lower force, resulting in faster 
disintegration of the film [35]. 
Higher value of folding endurance was shown for PEG 400 
containing formula compared with the others. On the other hand, 
soft and tough film was made with glycerin while PG produced the 
patchy and sticky film. At the same time, film plasticized with PEG 
400 exhibited good physical and mechanical properties such as 
tensile strength and %E as shown in table 3. These observations are 
in accordance with Ali MS et al. [36] and Choudhary et al. [37].  
So PEG400 was selected for further study for suitability in films 
formulation. 
T80% and %D2 min from the formulated films (F1, F10 and F11) are 
listed below in table 6. 
The release profile of lafutidine from formulas (F1, F10 and F11) 
which contain 30% w/w of (PEG 400, glycerin and PG) respectively 
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is displayed in fig. 6. No significant change (p>0.05) on the 
dissolution profile was seen by changing the plasticizer type because 
all the three plasticizers are water soluble, and they will diffuse out 
from the films in watery media making void spaces in the film 
through which diffusion of liquid happened enabling film breaking 
















Fig. 5: In vitro disintegration time in seconds of formulas prepared with different types of plasticizer, (mean±SD, n=3) 
 
Table 6: In vitro dissolution parameters from the prepared OFDFs (F1, F10 and F11) 
Formula code T80% (min) D2 min (%) 
F1 1.68±0.5 95±0.2 
F10 1.86±0.2 86±0.55 
F11 1.8±0.15 90±0.8 






























Fig. 6: Cumulative percentage of lafutidine released from formulas prepared with different types of plasticizer in phosphate buffer (pH 
6.8) at 37 °C, (mean±SD, n=3) 
 
Effect of the selected plasticizer concentration 
Formulas (F1, F7, F8 and F9) were used to study the effect of 
different concentrations of selected plasticizer PEG400 (30, 34, 24 
and 16 % w/w of the total film weight) on the in vitro DT, 
mechanical properties and the drug release profile of the oral film. 
Formulas (F1, F7, F8 and F9) showed that increasing the 
concentration of the selected plasticizer (PEG400) accompanied 
with decreasing in the DT as shown in fig. 7, this is due to the effect 
of PEG 400 as co-solvent which increases the solubility of non-polar, 
hydrophobic compounds by reducing the water squeezing out of 
them [39]. 
Jabir et al. 



















Fig. 7: In vitro disintegration time in seconds of formulas prepared with the different concentration of the selected plasticizer (PEG 400), 
(mean±SD, n=3) 
 
The mechanical properties of formulas (F1, F7, F8 and F9) were 
shown in table 3, which illustrated that as the plasticizer 
concentration increased the young's modulus and the tensile 
strength decreased. This is due to the fact that the intermolecular 
forces between polymer chains weakened upon increasing the 
concentration of plasticizer thus the rigidity of the three-
dimensional structure formed upon drying decreased [27]. 
Moreover, the %E was increased with increasing plasticizer 
concentration. These results can be explained by the (lubricity 
theory) which states that the plasticizers act as an interior emollient 
and enhance movement of the polymer chains [40]. 
The release profile of lafutidine from formulas (F1, F7, F8 and F9) 
which contain 30, 34, 24 and 16% w/w of PEG 400 respectively 
were shown in fig. 8, it was observed that as the concentration PEG 
400 increased the drug release rate significantly increased (p<0.05) 




Fig. 8: Cumulative percentage of lafutidine released from formulas prepared with the different concentration of PEG400 in phosphate 
buffer (pH 6.8) at 37 °C, (mean±SD, n=3) 
 
T80% and %D2 min from the formulated films (F1, F7, F8 and F9) are listed below in table 7. 
 
Table 7: In vitro dissolution parameters from the prepared OFDFs (F1, F7, F8 and F9) 
Formula code T80% (min) D2 min (%) 
F1 1.68±0.5 95±0.2 
F7 1.95±0.3 82.7±0.8 
F8 2.93±0.25 70±0.65 
F9 3.9±0.35 64±0.4 
All values were calculated as mean±SD, n=3, from the above results concerning physical, mechanical evaluations and release profile of the prepared 
OFDFs using different plasticizer types and concentrations. F1 will be subjected for the forward study. 
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Effect of surfactant type and combination  
Formulas (F1, F12 and F13) were used to study the effect of 
different types of surfactant (tween80, poloxamer407 and 
combination of both) on the in vitro DT, mechanical properties and 
the drug release profile of the OFDFs. 
Fig. 9 showed that the DT is significantly affected (p<0.05) by the 
type of surfactant so the best result (7 s) was obtained from F13 
upon a combination of the two types of surfactants (tween80 and 
poloxamer407) [42]. 
The mechanical properties of formulas (F1, F12 and F13) were 
listed in table 3, all the values of folding endurance, tensile 
strength, %E and young's modulus were within the range of 
accepted OFDFs. 
The release profile of lafutidine from formulas F1, F12 and F13 which 
contain tween80, poloxamer407 and combination of both surfactants, 
respectively was shown in fig. 10. It was observed that combination of 
surfactants(F13) significantly (p<0.05) increased the release of the drug 
from OFDFs, this is due to the additive effect of the water-soluble 
surfactant (poloxamer 407) which increases the solubility of the drug 
with a hydrophilic surfactant (tween80) that acts by decreasing surface 
tension and increasing wettability of the drug [12, 43]. 
The T80% and %D2 min values for formulas (F1, F12, and F13) 
were illustrated below in table 8. 
 
 




Fig. 10: Cumulative percentage of lafutidine released from formulas prepared with different types of surfactant in phosphate buffer (pH 
6.8) at 37 °C, (mean±SD, n=3) 
 
Table 8: In vitro dissolution parameters from the prepared OFDFs (F1, F12 and F13) 
Formula code T80%(min) D2 min (%) 
F1 1.68±0.5 95±0.2 
F12 3.7±0.3 64.6±0.8 
F13 0.96±0.25 100±0.1 
All values were calculated as mean±SD, n=3, Formula (F13) was chosen as the best one and can be further evaluated throughout the study 
depending on the previous outcomes that gave shorter DT, lower T80%
 
Effect of superdisintegrant  
,maximum D2 min and satisfactory mechanical properties. 
Formulas F13 and F14 listed in table 1 which contain croscarmellose 
5% and 0% respectively were allowed to study the DT and the 
release profile. 
Fig. 11 showed that croscarmellose significantly decreased (p<0.05) 
the DT of the OFDFs, this owing to the great capillary action of the 
superdisintegrant which quickly absorbs water into the film, 
swelling then giving a fast disintegration. 
Jabir et al. 




Fig. 11: In vitro disintegration time in seconds of formulas prepared with and without croscarmellose as a super disintegrant, (mean±SD, n=3) 
 
Fig. 12 showed the effect of croscarmellose on the release profile of 
lafutidine from formulas F13 (with superdisintegrant) and F14 
(without superdisintegrant). Faster release (p<0.05) was observed 
for F13 in comparison with F14 which is due to the highly porous 
structure of the superdisintegrant particles, help them to wick the 
liquid, swelling then break down and release of the drug [44, 45]. 
 
 
Fig. 12: Cumulative percentage of lafutidine released from formulas prepared with and without croscarmellose as superdisintegrant in 




 and % D2 min values for formulas (F13 and F14) were illustrated in table 9 below. 
Table 9: In vitro dissolution parameters from the prepared OFDFs (F13 and F14) 
Formula code T80% (min) D2 min (%) 
F13 0.96±0.25 100±0.1 
F14 2.13±0.4 75±0.6 
All values were calculated as mean±SD, n=3, From the previous results F13 which shown below in the fig. 13 was selected as the best formula for 
preparing of lafutidine as OFDF. 
 
  
Fig. 13: The best-selected formula F13 
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According to the results obtained; HPMC E5 showed the shortest in 
vitro DT accompanied with acceptable mechanical properties and 
dissolution behavior. PEG400 was the best plasticizer as it showed 
an improvement in the mechanical and physical characteristics of 
the lafutidine OFDFs. Formula (F13) which composed from 50% 
w/w HPMC E5 as a film forming polymer, 30% PEG400 as a 
plasticizer, 3.2% of each poloxamer407 and tween80 as surfactants, 
finally 3% croscarmellose added as superdisintegrant. This is 
regarded as an optimized formula with a low DT (7±0.5 s) and 80% 
of drug released within (0.96 min). 
When lafutidine administered in the form of OFDFs will be a 
potential novel drug dosage form for geriatric by providing faster 
release and better patient compliance. 
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